PFE vs. WAT: Pfizer vs. Waters Stock Comparison

Company Profile

Pfizer (PFE) and Waters (WAT) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but PFE is classified in Pharmaceuticals while WAT is classified in Life Sciences Tools & Services.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Pfizer (PFE) is heavily traded at around 33.67M shares per day, whereas Waters (WAT) sees a more moderate 816.72K — larger orders in the latter may require more patience and tighter control over order sizing.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Pfizer (PFE) at 4.47% and Waters (WAT) at 1.12% land near their industries’ usual ROE ranges, so capital efficiency looks broadly in line with peers on both sides.

Pfizer (PFE) at 6.34% retains a top-quartile share of revenue as profit, ahead of Waters (WAT) at 1.76%, which keeps about the industry-typical share.

Pfizer (PFE) at 33.38% operates in the top operating margin quartile, ahead of Waters (WAT) at 11.38%, which runs around its industry’s norm.

Profitability Metrics

Growth

Waters (WAT) at 6.99% is around its peer norm for revenue growth, while Pfizer (PFE) at -1.65% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Both Pfizer (PFE) at -3.55% and Waters (WAT) at 0.47% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Growth Metrics

Financial Strength

Short-term liquidity can only be read on one side of this pairing: Pfizer (PFE) shows current ratio of 1.42 against its industry benchmark, while Waters (WAT) has no reading this period.

Waters (WAT) at 0.34 carries an industry-typical debt-to-equity mix, while Pfizer (PFE) at 0.71 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Waters (WAT) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Pfizer (PFE) reports a yield of 7.30%, ranking against industry peers normally.

Pfizer (PFE) reports payout ratio above 100% at 245.71%, meaning dividends exceeded current-period earnings; Waters (WAT) pays no dividend (payout 0.00%).

Dividend Metrics

Valuation

Pfizer (PFE) at 41.99 is near its industry’s usual P/E ratio, while Waters (WAT) at 191.46 sits above its peer range — an unusually expensive price for WAT’s trailing earnings.

Pfizer (PFE) at 2.63 sits in the cheaper P/S ratio quartile while Waters (WAT) at 8.01 prices around its industry’s middle — PFE costs less per dollar of sales, though read it alongside growth and margins.

On P/B ratio, both Pfizer (PFE) at 1.88 and Waters (WAT) at 2.94 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics